Prolog Ventures is a venture capital firm based in Clayton, Missouri, established in 2000. The firm specializes in investments in startups and early-stage companies, primarily focusing on the life sciences and related information technology sectors. Prolog Ventures targets traditional healthcare opportunities as well as emerging fields such as nutrition, wellness, and green technology. Additionally, it invests in consumer health and wellness companies that offer innovative products and technologies in fast-moving consumer goods markets, including personal care, functional foods and beverages, medical foods, dietary supplements, and household care. The firm emphasizes investments in products that enhance the health and well-being of both people and companion animals through proprietary ingredients, formulations, and delivery technologies. Prolog Ventures primarily operates within North America.
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.
CleanSlate UV
Series A in 2020
CleanSlate UV allows staff, patients and visitors to sanitize their personal items (such as phones, tablets and badges) while they wash or sanitize their hands. This helps improve hand hygiene and reduce the risk of hospital acquired infections. Its mission is simple: eliminate pathogens on mobile devices through the use of effective and easy-to-use UV products. We do this by designing technologies that people will actually use, backed by science reflective of real-world conditions. CleanSlate harness the power of UV light to kill the most dangerous bacteria without damaging expensive touch screens.
Covercress
Venture Round in 2020
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
Kinnos
Series A in 2020
Kinnos Inc. is a biotechnology company based in Brooklyn, New York, that specializes in improving disinfection practices through innovative color technology. Founded in 2014, the company manufactures a powdered additive called Highlight, which enhances the visibility of disinfectants, ensuring thorough cleaning and compliance during disinfection processes. Highlight provides real-time color-change feedback, allowing users to see where disinfectants have been applied, which helps prevent disease outbreaks on various surfaces. In addition to Highlight, Kinnos also offers Highlight Wipes, a dispensing machine for wipes, and Highlight Powder, another form of their disinfectant additive. The company's mission is to empower individuals to disinfect with confidence and to enhance public health through effective and visible disinfection.
bioClarity
Venture Round in 2019
BioClarity is dedicated to solving the skincare needs of young adults by fusing nature and science to create the next generation of acne fighting products.
Covercress
Venture Round in 2018
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
TOMA Biosciences
Series C in 2018
TOMA Biosciences, Inc. is a genomics company based in Foster City, California, focused on developing reagent kits and cancer testing technologies that assist laboratories and researchers in identifying genomic changes in tumors. The company offers TOMA OS-Seq, an oncology-focused gene analysis solution that leverages advanced next-generation sequencing technology to detect clinically significant alterations in tumor DNA. This information is crucial for physicians to optimize treatment strategies for cancer patients by providing insights into the genomic errors present in their tumors. TOMA Biosciences serves a wide range of clients, including laboratories, hospital systems, and research institutions globally, and aims to improve clinical outcomes through its innovative testing solutions. The company has been operational since its incorporation in 2011.
Spindrift
Series B in 2018
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.
Benson Hill
Series B in 2017
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.
Spindrift
Series B in 2017
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.
Covercress
Venture Round in 2017
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
SchoolCare
Series B in 2016
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.
SchoolCare
Debt Financing in 2016
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.
Intellicyt
Venture Round in 2015
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.
Veran Medical Technologies
Venture Round in 2015
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
Benson Hill
Series A in 2015
Benson Hill is a crop improvement company that unlocks the natural diversity of plants and empowers innovators with a revolutionary crop design platform to develop healthier and more sustainable food and ingredients. Benson Hill empowers innovators to develop more healthy, flavorful, and sustainable food by unlocking the natural genetic diversity of plants. Benson Hill’s CropOS™ platform combines machine learning and big data with breeding techniques and plant biology to drastically accelerate and simplify the product development process.
NeuroLutions
Venture Round in 2015
NeuroLutions Inc. is a company based in St. Louis, Missouri, focused on developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled due to neurological injuries, particularly stroke survivors. Founded in 2007, NeuroLutions employs non-invasive electroencephalography (EEG) technology to capture brain activity without the need for implanted electrodes. The EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. This innovative approach enables users to facilitate muscle re-education and helps maintain or improve their range of motion, thereby enhancing rehabilitation outcomes for individuals with movement impairments.
Covercress
Series A in 2015
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
Veniti
Series C in 2015
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.
Veran Medical Technologies
Venture Round in 2014
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
AirXpanders
Series E in 2014
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
Veran Medical Technologies
Debt Financing in 2014
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
Spindrift
Venture Round in 2014
Spindrift Beverage Co., Inc., founded in 2010 and based in Newton, Massachusetts, specializes in producing unsweetened sparkling beverages made with real squeezed fruit. The company offers a range of drinks that combine triple-filtered sparkling water with authentic fruit flavors, such as lemon, raspberry lime, and strawberry, without any artificial sweeteners. Spindrift aims to provide consumers with refreshing beverages that promote a healthy and active lifestyle through the use of real ingredients.
Singulex
Series G in 2013
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.
EndoStim
Series D in 2013
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Veniti
Series B in 2013
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.
AirXpanders
Series E in 2013
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
Intellicyt
Venture Round in 2013
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.
Akermin
Venture Round in 2013
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.
EndoStim
Series C in 2013
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
AirXpanders
Series D in 2012
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
Zeel
Seed Round in 2012
Zeel is a company that provides on-demand massage services, allowing customers to book high-quality massages from licensed and vetted therapists at their homes, hotels, workplaces, or events. Founded in 2012 and launching its app in 2013, Zeel aims to disrupt the massage industry by offering convenience and flexibility, enabling bookings as soon as one hour in advance or up to a month ahead. Customers can choose from various massage types, including Swedish, deep tissue, prenatal, sports, and couples massages, all at a set price that includes tax and tips. The therapists are thoroughly vetted, licensed, insured, and trained to ensure top-notch customer service. In 2013, Zeel introduced Massage Zeelot, a subscription service that provides customers with at least one in-home massage per month at a discounted rate, along with a professional-grade massage table for personal use.
Singulex
Series F in 2012
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.
AirXpanders
Series D in 2012
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
The Nest Collective
Venture Round in 2012
The Nest Collective, Inc. produces organic food and snacks for babies, toddlers, and kids. The company was incorporated in 2008 and is based in Emeryville, California.
EndoStim
Venture Round in 2011
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Veran Medical Technologies
Series B in 2011
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
Veniti
Series A in 2011
VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.
EndoStim
Series B in 2010
EndoStim, Inc. is a medical device company based in Dallas, Texas, specializing in neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Founded in 2009, the company has developed a microstimulator technology that restores normal esophageal function by targeting the weak or dysfunctional lower esophageal sphincter (LES) muscle. This innovative approach offers long-term control of reflux symptoms while minimizing the gastrointestinal side effects often associated with traditional anti-reflux surgery. EndoStim is actively conducting clinical trials to secure FDA approval for its therapies, which aim to address not only GERD but also urinary urge incontinence. The company distributes its products across Europe, Asia, and Latin America, focusing on improving the quality of life for patients suffering from these conditions.
Akermin
Series B in 2010
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.
Divergence
Series C in 2009
Divergence is a research and development company dedicated to the discovery of effective and ecologically sound strategies for the control of parasites and other pests. The Company's initial focus is on parasitic nematodes, one of the world's major pest groups. Nematodes are roundworms that cause billions of dollars in damage annually to numerous crops, including soybeans, corn, cotton, strawberries, and bananas. Nematodes causing important human diseases include hookworm, whipworm, roundworm (Ascaris), and the filarial worms responsible for lymphatic filariasis and onchocerciasis.
Veran Medical Technologies
Series B in 2008
Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.
Asoyia
Venture Round in 2008
Asoyia, LLC produces soybeans and soybean oil.
CS-Keys
Series A in 2008
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.
Akermin
Series A in 2007
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.
Chlorogen
Venture Round in 2007
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.
Singulex
Series D in 2007
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.
Dreamerz Foods
Series B in 2007
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.
The Natural Dentist
Series B in 2007
The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.
Attune Foods
Series B in 2007
Attune Foods, Inc. offers probiotic wellness bars. It offers wellness bars in various flavors, including dark chocolate, chocolate crisp, mint chocolate, and blueberry vanilla, as well as chewy chocolate, peanut butter and chocolate, mango peach, wild berry, strawberry bliss, and lemon crème. Attune Foods, Inc. was founded in 2006 and is headquartered in San Francisco, California.
AirXpanders
Series A in 2007
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
AirXpanders
Venture Round in 2006
AirXpanders, Inc. was a medical device company founded in 2005 and headquartered in San Jose, California. It specialized in designing, manufacturing, and distributing devices aimed at improving breast reconstruction procedures. The company developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device used for tissue expansion in patients undergoing two-stage breast reconstruction after mastectomy. AirXpanders operated in Australia, the United States, and Europe, focusing on enhancing the experience and outcomes for patients requiring breast reconstruction. However, on September 25, 2019, the company filed for Chapter 7 bankruptcy and ceased operations.
Dreamerz Foods
Series A in 2006
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.
The Natural Dentist
Series B in 2006
The Natural Dentist, Inc., founded in 1995 and based in Medford, Massachusetts, specializes in manufacturing oral care products, including mouth rinses and toothpastes. The company, which was previously known as Woodstock Natural Products Inc. before rebranding in 2005, provides its products through various retail channels, including physical stores and online platforms. In 2010, The Natural Dentist was acquired by Revive Personal Products Company. The company is part of a broader portfolio that includes over-the-counter consumer healthcare brands, reflecting its commitment to promoting oral health and hygiene.
Travanti Pharma
Series B in 2006
Travanti Pharma is a privately held company that focuses on the design, development, and marketing of innovative drug delivery platforms aimed at enhancing the safety, compliance, effectiveness, and ease of medication administration. The company's technology includes an electronic drug delivery system that employs controlled low-level electrical energy to safely transport drugs through the skin or other areas of the body. Additionally, Travanti Pharma offers a wearable electronic disposable drug delivery system, which is a portable and disposable solution for transdermal medication delivery. Through these advanced technologies, Travanti Pharma seeks to improve patient outcomes and streamline the drug delivery process.
Singulex
Series C in 2006
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.
EraGen Biosciences
Series A in 2006
EraGen Biosciences, Inc. is a biotechnology company based in Madison, Wisconsin, that specializes in developing, manufacturing, and marketing molecular reagent products and software for research and clinical testing markets. The company provides molecular diagnostic assays designed for the early detection and monitoring of cancer, genetic disorders, infectious diseases, and other genetic-based conditions. Its product offerings include molecular diagnostic tests, analyte specific reagents, in vitro diagnostic reagents, and research use only reagents. Additionally, EraGen Biosciences offers MultiCode-PLx and MultiCode-RTx Analysis Software, which enable users to create customized templates for assay layouts and conduct quantitative and qualitative analyses, respectively. The company primarily serves clinical laboratories and medical researchers, distributing its products across the United States and Canada. Founded in 1994 as Sulfonics, Inc., it adopted the name EraGen Biosciences, Inc. in 1999.
Akermin
Series A in 2005
Akermin is based in St. Louis, Missouri, and was formed in 2004 to commercialize breakthrough stabilized enzyme technology invented at Saint Louis University. In 2008, Akermin demonstrated its prototype of a fully functioning biofuel cell operating on methanol fuel and using stabilized laccase to replace the metal catalyst in conventional cathodes. Commercial applications in wireless sensors and military uses are their primary focus. Development for the use of stabilized enzymes in the food processing, biofuels, chemical, and pharmaceutical industries is under way.
Chlorogen
Series B in 2005
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.
Quick Study Radiology
Series C in 2005
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.
Brand New Brands
Series A in 2005
Brand New Brands is a groundbreaking new company that brings together the entrepreneurial spirit of a start-up and the resources of an established corporation to create new foods and beverages that promote health and wellness. Brand New Brands uses a portfolio-based incubator model to develop and market the highest potential new functional food business opportunities for the U.S. marketplace. Core to their approach is the commitment to create food and beverage products that are efficacious (by medical standards), honest and transparent in their claims, and satisfying to eat or drink. By vetting and assessing the potential of scores of new product concepts, they take the most promising opportunities and fuse them with talented, passionate and proven entrepreneurial teams who turn ideas into thriving new ventures. They focus their efforts and resources by innovating “category-creating” brand platforms that are capable of crossing over from niche markets to the mainstream in three to five years. They only pursue opportunities where they can claim distinct competitive advantages over large food companies through IP, brand creation or non-traditional distribution. Their strategy is to take the most promising new nutritional technologies and deliver them to the marketplace through great-tasting products with engaging “lifestyle” brands that educate and attract loyal customers and progressive retail partners. They take opportunities to market that are likely to scale quickly due to the convergence of scientific advances, consumer readiness and media attention.
Travanti Pharma
Series A in 2005
Travanti Pharma is a privately held company that focuses on the design, development, and marketing of innovative drug delivery platforms aimed at enhancing the safety, compliance, effectiveness, and ease of medication administration. The company's technology includes an electronic drug delivery system that employs controlled low-level electrical energy to safely transport drugs through the skin or other areas of the body. Additionally, Travanti Pharma offers a wearable electronic disposable drug delivery system, which is a portable and disposable solution for transdermal medication delivery. Through these advanced technologies, Travanti Pharma seeks to improve patient outcomes and streamline the drug delivery process.
Zystor
Series A in 2004
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
Quick Study Radiology
Series C in 2004
Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.
Divergence
Venture Round in 2004
Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.
Chlorogen
Series A in 2003
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.
Divergence
Venture Round in 2002
Divergence is a research and development company focused on creating effective and environmentally sustainable methods for controlling parasites and pests, particularly parasitic nematodes. These roundworms are significant agricultural pests, inflicting billions of dollars in damage to various crops, such as soybeans, corn, cotton, strawberries, and bananas. Additionally, some nematodes are responsible for serious human diseases, including hookworm, whipworm, and roundworm infections, as well as filarial infections that lead to lymphatic filariasis and onchocerciasis. By developing innovative genes and molecules, Divergence aims to address the challenges posed by these harmful organisms in both agricultural and medical contexts.
Inoveon
Series B in 2002
Inoveon Corporation is a medical services company based in Oklahoma City, Oklahoma, focused on providing solutions for the detection, staging, and monitoring of eye diseases, specifically diabetic retinopathy, macular degeneration, and glaucoma. Founded in 1997, Inoveon offers advanced technologies, including iScan, which assesses diabetic retinopathy and macular edema, and the INOVEON System, designed to enhance compliance rates among physician groups for managing these conditions. As a subsidiary of Ifa Systems Ag since 2010, Inoveon aims to support healthcare providers in delivering quality care to patients with eye-related diseases, ultimately working to preserve eyesight.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.